Journals / Turkish journal of nephrology (Online) / 2022 / Cilt: 31 - Sayı: 2

Clinicopathological Features and Kidney Survival in Rapidly Progressive Glomerulonephritis: A Single-Center Experience

Pages
138–147
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Kidney biopsy is essential for the kidney prognosis for rapid diagnosis, especially in young patients with suspected rapidly progressive glomerulonephritis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Advanced age, need for dialysis and high creatinine values at the time of admission, anti-glomerular basement membrane antibody positivity, pulmonary hemorrhage, and fibrous crescents on pathology are known poor prognostic factors in rapidly progressive glomerulonephritis.
📊
Key Findings & Data:Methods: This study was made with 52 patients diagnosed with type 1 and type 3 rapidly progressive glomerulonephritis.
💡
Conclusion & Impact:Kidney biopsy is essential for the kidney prognosis for rapid diagnosis, especially in young patients with suspected rapidly progressive glomerulonephritis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Advanced age, need for dialysis and high creatinine values at the time of admission, anti-glomerular basement membrane antibody positivity, pulmonary hemorrhage, and fibrous crescents on pathology are known poor prognostic factors in rapidly progressive glomerulonephritis. Our study aimed to determine the clinical, laboratory, and pathological factors affecting the kidney prognosis in the progression to end-stage kidney failure disease in our rapidly progressive glomerulonephritis patients. Methods: This study was made with 52 patients diagnosed with type 1 and type 3 rapidly progressive glomerulonephritis. The study continued with 37 eligible patients. Results: The patients’ mean age was 52.3 ± 11.06 and 22 (59.4%) were male. In 6 patients (16.2%), anti-glomerular basement membrane positivity, in 11 patients (29.7%), cytoplasmic anti-neutrophilic cytoplasmic antibody positivity, and in 20 patients (54.1%), perinuclear anti-neutrophilic cytoplasmic antibody positivity was detected. Parathyroid hormone value was higher in the perinuclear anti-neutrophilic cytoplasmic antibody-positive group at the time of biopsy (P = .005). Serum sodium levels were lower at the biopsy time in the patient group with a crescent rate above 65% (P = .014). Patients with end-stage kidney failure disease were younger, and their serum sodium levels expressively were lower at the biopsy time (P = .006, P = .02 respectively). When the risk factors affecting end-stage kidney failure disease were examined in multivariate regression analysis, it was observed that while sodium and parathyroid hormone values were not risk factors at the time of biopsy, age (P = .048) and time until diagnosis were risk factors (P = .048). Conclusion: In our study, the risk factors affecting end-stage kidney failure disease progression in rapidly progressive glomerulonephritis patients were age and the time until diagnosis. Kidney biopsy is essential for the kidney prognosis for rapid diagnosis, especially in young patients with suspected rapidly progressive glomerulonephritis.

🔖

Cite This Article

SELEN, T., OĞUZ, E. G., ŞAHİN, H., AYLI, M. D., ATILGAN, K. G., EBİNÇ, F. A., OKYAY, G. U., EKSİN, M. A. (2022). Clinicopathological Features and Kidney Survival in Rapidly Progressive Glomerulonephritis: A Single-Center Experience. Turkish journal of nephrology (Online), Cilt: 31 - Sayı: 2, 138–147. https://ajindex.com/articles/612804

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003
  2. 63(3):1164-1177. [CrossRef] 2. Andrassy K, Küster S, Waldherr R, Ritz E. Rapidly progressive glomerulonephritis: analysis of prevalence and clinical course. Nephron. 1991
  3. 59(2):206-212. [CrossRef] 3. Hénique C, Papista C, Guyonnet L, Lenoir O, Tharaux PL. Update on crescentic glomerulonephritis. Semin Immunopathol. 2014
  4. 36(4):479-490. [CrossRef] 4. Moroni G, Ponticelli C. Rapidly progressive glomerulonephritis: early treatment is a must. Autoimmun Rev. 2014
  5. 13(7):723-729. [CrossRef] 5. Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults: a systematic review. BMC Nephrol. 2010
  6. [CrossRef] 6. Wu T, Peng J, Meng T, et al. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med. 2019
  7. 18(5):3984-3990. [CrossRef] 7. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guid eline for glomerulonephritis Kidney Int Suppl. 2012
  8. 2(2):139-274. 8. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016
  9. 75(9):1583-1594. [CrossRef] 9. Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanism and therapy. Am J Kidney Dis. 1988
  10. 11(6):449-464. [CrossRef] 10. Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004
  11. 66(4):1535-1540. [CrossRef] 11. Sanavi S, Afshar R. An unusual presentation of antineutrophil cytoplasmic antibody-associated vasculitis: discrepancy between histopathology and clinical presentation. Iran J Kidney Dis. 2011
  12. 5(5):347-350. 12. Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture’s syndrome. South Med J. 2002
  13. 95(12):1411-1418. 13. Derebail VK, Falk RJ. ANCA-associated vasculitis - refining therapy with plasma exchange and glucocorticoids. N Engl J Med. 2020
  14. 382(7):671-673. [CrossRef] 14. Hildebrand AM, Huang SH, Clark WF. Plasma exchange for kidney disease: what is the best evidence? Adv Chronic Kidney Dis. 2014
  15. 21(2):217-227. [CrossRef] 15. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020
  16. 382(7):622-631. [CrossRef] 16. Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: a 4-year, single center experience. Am J Ki